{"name":"Gyala Therapeutics","slug":"gyala-therapeutics","ticker":"","exchange":"","domain":"gyala.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZElKdk1jdjNlUzVUdllydWJ6Smx0U0oxZV9kN2JvVC1fZlQ1RHJ3Yld3V3FjdEZLMkQ4RUI0WVFNeG5VY0p5RnJzZUt0WEx3NTllcmsyN0xhLWFHTnZfQ1pxeVNXbV82clpCWTRGMDFzOGc1dWplek51Y2I2SkhKUUtJVm9CZThMSzFGVENiQ0tZSDhOQ2JqMzNmUUd3d2VNWVJ0d2VPeUdRME0?oc=5","date":"2026-02-10","type":"trial","source":"The Pharma Letter","summary":"Gyala launches first-in-class CD84 CAR-T trial in acute leukemias - The Pharma Letter","headline":"Gyala launches first-in-class CD84 CAR-T trial in acute leukemias","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxOUmVueFhROHNvTkhTZWl5SGNRRXR3c0I5VlpTSXdKaTBodERhdm40S0JrNnB5UEpNVUNOZGtpbW03S2EtOW9CX2ZXYXVxbWpGWEZycU9rUHBSNW1zTFh5YnF4VzJVR1N0ai1VTHdHTjVudTN2eFZVVDloeVk3NERsNjFlN21DWXdsOWdpMFc1eTNrYzJaUzAzTV9EMkJydEc5aVhpQ2U0eXc2cHl6enhCU2FmWVkxOVFwajlwOHJrTWlMNnBGcE1kdEtHeXNiVFJwX2VUYjJHUXpxQ01YRVVDc2pJd3M1aFJQaVhrVW1lV1loQV9LaEpYdG1CRkdQVUU5UHJoOG1meENTV1Nfdjk5dWlB?oc=5","date":"2026-02-10","type":"trial","source":"PR Newswire","summary":"Gyala Therapeutics initiates Phase I/IIa clinical trial of a CAR-T cell therapy in acute leukemias with limited treatment options - PR Newswire","headline":"Gyala Therapeutics initiates Phase I/IIa clinical trial of a CAR-T cell therapy in acute leukemias with limited treatmen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxNYmcwY2lEVnZyU3I4VUphbHMtUnctVjZySHRoQmh5bGdOOGVZTzVkNms2WFo5TldrRFdvUkwwbk5uSXhGYjhrWkliMzI4eFFSZUdQWEdGVHdCZ1VPa3E3cFItWXRtdGxtbVczVUN1LWViRmtnaTRVc08wclNzeXQwdmlSRlRLTkxyUXlELXRaOFRQRnB0UGUweHNPR2oxVGhadGdsc0FNT0doOWktWFE5cWVmX3djaUlNNXZieVNCNXIyYjVWMDdpMXIyLUFqUWdCM3d4V2ZwRllOTzhSUHd4RURqdlc1QzhwMHc2c1pfRUtycGF4TkxoUW9SWnhXRXM?oc=5","date":"2026-02-10","type":"trial","source":"BioSpace","summary":"Gyala Therapeutics initiates Phase I/IIa clinical trial of a CAR-T cell therapy for acute leukemias with limited treatment options - BioSpace","headline":"Gyala Therapeutics initiates Phase I/IIa clinical trial of a CAR-T cell therapy for acute leukemias with limited treatme","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNd0hmek9tYm1ReWkyclpNdlhnWTdjTTAtRUZwQmdvSHIwREZRcW90c0h3eDJja28zRXhOM0ZSVkN4bU0yREg1ekdnUVVDSW5wRWpBY1VtS0o4Y1RYaWVrM0hubDZTRm9lQUozM1hrNmZDNFhZUzVHNWIxTHBOckJrNGZLOWFJdw?oc=5","date":"2026-01-06","type":"deal","source":"PharmTech.com","summary":"Amgen Acquires UK Biotech Dark Blue Therapeutics - PharmTech.com","headline":"Amgen Acquires UK Biotech Dark Blue Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxNcXdpV3J2NElrWmg5ZE42b0JETFdmZFE4TW41dDdJX3NrYUY5ZVFCV0VoV081dWlTTjAzcmhEU0stQ2Z0cFJwSU9zRk5pTFpUdm5wYnNvTlE0Vk9zMDhuVE81VHFUbFY1b25lNFY2YXBteWRaRkNOZTNVUEFVcGpUNTgtR1FUUTlSc2pkTVF5RnBxQnVCNE43WmlLTkxjYXY0azNLdkotR2JUcnVOZEhzWDhFRDR6M0FNSURraFNmaTBDUy04a3p1eXp5ZGN0UVdLY1Z1MEROazl2R1BPVjFVRkZMQVpQR2FLb0dHejZZOVRNOFFQaTFWTHd1NUU4cTcta3QtOW1BS19pUDI0QkJ4ZDlHb3FKQ2tT?oc=5","date":"2025-09-15","type":"pipeline","source":"PR Newswire","summary":"Gyala Therapeutics unveils first-in-class CAR-T therapy targeting CD84 showing strong preclinical efficacy in hard-to-treat leukemias - PR Newswire","headline":"Gyala Therapeutics unveils first-in-class CAR-T therapy targeting CD84 showing strong preclinical efficacy in hard-to-tr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOb0h3LWdwZExfV04wM2p5R1M2d2VTY3pQbUpCMmFYbGRiQ0l2NlJQWmxnV0VZNFVDNkpFUjdNNXJXZGhqbV9PRmxMQUpsM25vQnBoWktmZDFrNTVoYXdteHdjcG15S09CejNCRmxDUGhuc1ZiMXZQMEhVMmdTZzFkUTBtcGszdw?oc=5","date":"2024-03-06","type":"pipeline","source":"BioPharma Dive","summary":"European VC Invivo readies its latest fund to back new biotechs - BioPharma Dive","headline":"European VC Invivo readies its latest fund to back new biotechs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOMUZlRDQtbzVxTU9HVnltUjFZOXlNdUFqV3FvMG5EaDZ4QUFINzVhNlktMllxQkVhUUhLZXJVRHB5TktIWGNrYXB1T1VYdDhaLWlJVEQtUTdid056aW1CdFNDTHhrMDdUTUpTQzFsR29zRExDWURUelo1N0Z5NTFOZm9wSGtmV2xXVENSZWhGNUI?oc=5","date":"2021-06-26","type":"pipeline","source":"EU-Startups","summary":"101 Top Biotechnology Startups and Companies in Spain (2021) - EU-Startups","headline":"101 Top Biotechnology Startups and Companies in Spain (2021) - EU","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}